Trends in laboratory detection of *Burkholderia pseudomallei* and their antibiotic susceptibility pattern from clinical samples over twenty one years from 2001 to 2021 in a tertiary care hospital of Bangladesh

LoLoBarai1, Mali Rani Saha1, Tanjila Rahman1, Marium Sukanya1, Jninat Jafri1, Jannatul Ferdous1, Md. Rokibul Hasan1, M.S.A Jilani2

1Department of Microbiology, Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders (BIRDEM), Dhaka, Bangladesh, 2Department of Microbiology, Ibrahim Medical College Dhaka, Bangladesh.

Abstract
Melioidosis, a highly fatal infectious disease caused by *Burkholderia pseudomallei*, is largely under-recognized and underreported due to lack of alertness of health care professionals. The real burden of melioidosis in our country is poorly understood. Here, we have documented laboratory isolation trends of *B. pseudomallei* from different clinical samples sent to our Microbiology department from 2001 to 2021, with the aim to increase awareness among clinicians and microbiologists in the health care community of Bangladesh. A total of 86 *B. pseudomallei*, isolated from culture of different clinical samples in 68 melioidosis cases were studied retrospectively from hospital records. Antimicrobial susceptibility result by Kirby Bauer disk diffusion method was also analyzed. The most commonly affected age group was 46-60 years and majority of them (88.2%) had diabetes mellitus. Septicaemia (51.5%) was the most common presentation followed by skin and subcutaneous tissue abscess (29.4%), septic arthritis (16.2%), UTI (13.2%), pneumonia (10.3%), visceral abscess in lung (5.9%), liver (5.9%), spleen (7.3%) etc and death was reported among 32.5% cases. One case of laboratory acquired melioidosis was diagnosed from cleaner of our Microbiology laboratory. Average isolation rate of *B. pseudomallei* was 5.6 per year in our centre. The organism was isolated most frequently from blood (40.7%) and pus/wound swab (30.2%) samples. All the isolates were highly sensitive (>95%) to ceftazidime, carbapenem, piperacillin-tazobactum, amoxicillin-clavulanic acid and tetracycline, but 53.4% and 67.2% of our strains were recorded sensitive to co-trimoxazole and ciprofloxacin by disc diffusion method. In conclusion, melioidosis might be included as notifiable disease in national surveillance system of Bangladesh to provide key part in priority-setting, planning, also monitoring and evaluation of the disease control programs. Prompt early diagnosis and appropriate antibiotic administration are the critical steps to prevent mortality and morbidity from this deadly disease.

Keywords: Melioidosis, *Burkholderia pseudomallei*, antibiotic susceptibility, Bangladesh

Introduction
Bangladesh is documented as a ‘definite’ endemic country for melioidosis1, a potentially fatal infectious disease caused by *Burkholderia pseudomallei* which requires intensive antimicrobial treatment. Limmathurosakul et al2 estimated total incidence of melioidosis case globally and in Bangladesh would be 1,65,000 and 16,931 using a statistical model in 2015. So far, approximate 54 culture positive cases were reported1-4 from our country. Therefore, it is presumed that melioidosis is severely underreported in Bangladesh. Although melioidosis is known for a century years ago, most of the physicians still missed and misdiagnosed the disease as it produces protean clinical manifestation and mimic tuberculosis or other pyogenic bacterial infections. A lack of familiarity of microbiologists with the cultural characteristics of *B. pseudomallei* has also resulted in failure of recognition, identification, diagnosis and treatment. Awareness and high index of suspicion from both clinical and microbiology lab personnel are a prerequisite for correct identification of the offending organism. Laboratory diagnosis of

Correspondence:
LoLoBarai
MBBS, FCPS, PhD, Associate Professor
Department of Microbiology, BIRDEM General Hospital
122 Kazi Nazrul Islam Avenue, Dhaka-1000
E-mail: barai_lovely@yahoo.com

08
B. pseudomallei manifestation and mimic tuberculosis or other pyogenic diseases with ordinary antibiotic regimen is ineffective and disease (up to species level) is very much crucial as treating it staff frequently mistake it as contaminants. Typical µg) and amikacin (30 µg) by disc diffusion technique9.

Materials and Methods

All B. pseudomallei detected from clinical samples sent to the Microbiology laboratory of BIRDEM General Hospital, Dhaka, Bangladesh over a period of 21 years were analyzed retrospectively in this study. Organism was isolated from blood, urine, respiratory secretions, pus and wound swab from in and out patients sample during 2001 to 2021. Samples were cultured in Blood agar and MacConkey agar media. B. pseudomallei was identified by typical colony morphology in routine laboratory and selective Ashdown agar media, Gram staining (bipolar staining), motility, biochemical tests, and inherent resistance pattern to colistin and aminoglycosides . Monoclonal antibody based latex agglutination test (Melioidosis Research Center, KhonKaen, Thailand) was performed for the final identification and confirmation of B. pseudomallei. The isolates were tested for susceptibility to ceftazidime (30 µg), meropenem/imipenem (10 µg), piperacillin-tazobactam (30 µg), amoxicillin-clavulanic acid (30 µg), tetracycline, TMP-SMX (1.25/23.75 µg), gentamicin (10 µg) and amikacin (30 µg) by disc diffusion technique.

Results

A total of 86 B. pseudomallei isolated from culture of different clinical samples from 68 patients were analyzed. The patients were diagnosed to be suffering from melioidosis based on clinical symptoms and microbiological examination. The sociodemographic and clinical records of these patients are given in Table 2. Of the total patients, 57 were male and 11 were female. All of them were adults (mean age 47.9±12.4), except 1, who was 11 years old presented with septicaemia and neck abscess. The most commonly affected age group was that between 46-60 years. Most of them (88.2%) presented with diabetes mellitus. Occupational history revealed 17 (25%) were farmers, 7 (10.3%) overseas workers returned from Thailand, Brunei, Malaysia, Singapore and Qatar and rest were construction worker, businessman, carpenter, housewife etc. One case of laboratory acquired melioidosis was diagnosed from cleaner of our Microbiology department in the year 2020. Fever (100%) with cutaneous lesion (32.5%) was the predominant symptoms among the study population. Septicaemia (51.5%) was the most common presentation.
along with skin and subcutaneous tissue abscess (29.4%), septic arthritis (16.2%), UTI (13.2%), pneumonia (10.3%), visceral abscess in lung (5.9%), liver (5.9%), spleen (7.3%) and also abscess in other sites (Table 2). Among the cases culture was positive from 51.5% of blood followed by pus/wound swab (38.2%), urine (16.2%), respiratory secretions (10.3%) and joint fluids (10.3%). Out of 68 melioid cases, 22 died, while the outcome of 11 was unknown. High number of cases were identified during 2015 (13/68, 19.1%) and 2019 (10/68, 14.7%) by culture given in Table 3. Out of 86 B. pseudomallei isolates, 35 (40.7%) were isolated from blood sample, 11 (12.8%) from urine, 26 (30.2%), 7 (8.1%) from pus/wound, joint fluid & sputum/tracheal aspirated sample respectively (Table 4). All (100%) the isolates were sensitive to ceftazidime and piperacillin-tazobactum. Majority of them also sensitive to imipenem (98.3%), amoxicillin-clavulanic acid (96.1%) where as 53.4% and 67.2% were found sensitive to co-trimoxazole and tetracycline by disc diffusion method (fig 1).

Table 2: Sociodemographic and clinical records of 68 culture confirmed cases of melioidosis in BIRDEM General Hospital from year 2001 to 2021

| Antimicrobial agents | Disk content (µg) | Resistant | Intermediate | Susceptible |
|----------------------|------------------|-----------|--------------|-------------|
| 1. Mean age in years (±SD) | 47.9±12.4 | 1 (1.5) | 6 (8.8) | 21 (30.9) |
| • <15 years | 1 (1.5) | 6 (8.8) | 21 (30.9) | 31 (45.6) |
| • 15-30 years | 6 (8.8) | 21 (30.9) | 31 (45.6) | 9 (13.2) |
| • 31-45 years | 21 (30.9) | 31 (45.6) | 9 (13.2) | |
| • 46-60 years | 31 (45.6) | 9 (13.2) | | |
| • >60 years | 9 (13.2) | | | |
| 2. Sex | | | |
| • Male | 57 (83.82) | | | |
| • Female | 11 (16.18) | | | |
| 3. Occupation | | | |
| • Farmer | 17 (25) | | | |
| • Businessman | 7 (10.29) | | | |
| • Housewife | 9 (13.23) | | | |
| • Construction worker | 2 (2.94) | | | |
| • Overseas worker(Thailand, Brunei, Malaysia, Singapore, Qatar) | 7 (10.29) | | | |
| • Others (teacher, student, political person, clerical jobs, carpenter, Microbiology lab etc) | 17 (25) | | | |
| • Unknown | 9 (13.23) | | | |
| 4. Risk factors | | | |
| • DM | 60 (88.23) | | | |

5. Symptoms
- Fever
- Cough
- breathlessness
- Wt loss
- Dysuria/burning micturition
- Joint pain/swelling
- Abdominal pain
- Diarrhea
- Rash
- Anorexia
- Backache

6. Major clinical presentation
- Septicaemia
- Pneumonia
- Lung abscess
- Liver abscess
- Splenic abscess
- Prostatic abscess
- UTI
- Septic arthritis
- Electrolyte imbalance
- Skin/Subcutaneous tissue abscess
- Bartholin abscess
- Septic shock
- Fascial cellulitis
- Epidural abscess

7. Culture positive samples
- Blood
- Urine
- Pus and Wound swab
- Sputum/Tracheal aspirate
- Joint fluid

8. Outcome
- Cured
- Died
- Lost to Follow up
Table 3: Trends of detection of *B. pseudomallei* positive cases in Microbiology laboratory from 2001 to 2021

| Year | Trends of detection positive cases | % |
|------|-----------------------------------|---|
| 2001 | 1                                 | 1.5 |
| 2009 | 2                                 | 2.9 |
| 2010 | 2                                 | 2.9 |
| 2013 | 5                                 | 7.4 |
| 2014 | 3                                 | 4.4 |
| 2015 | 13                                | 19.1 |
| 2016 | 8                                 | 11.8 |
| 2017 | 7                                 | 10.3 |
| 2018 | 9                                 | 13.3 |
| 2019 | 10                                | 14.7 |
| 2020 | 2                                 | 2.9 |
| 2021 | 6                                 | 8.8 |
| Total (12 years) | 68 | 100 |

Table 4: Frequency of isolation of *B. pseudomallei* in different clinical sample from 2001 to 2021 (n=86)

| Year | Frequency of isolation in | Blood | Urine | Pus/wound swab | Joint fluid | Resp Secretion |
|------|---------------------------|-------|-------|----------------|-------------|----------------|
| 2001 |                           | -     | -     | 1              | -           | -              |
| 2009 |                           | -     | 2     | 1              | -           | -              |
| 2010 |                           | -     | 1     | -              | -           | 1              |
| 2013 |                           | 3     | -     | 3              | 1           | -              |
| 2014 |                           | 1     | -     | 1              | 1           | 1              |
| 2015 |                           | 8     | 2     | 4              | 1           | 1              |
| 2016 |                           | 5     | 2     | 5              | 1           | 1              |
| 2017 |                           | 5     | 2     | 1              | -           | -              |
| 2018 |                           | 6     | 2     | 1              | 1           | -              |
| 2019 |                           | 5     | 1     | 3              | 1           | 1              |
| 2020 |                           | -     | -     | 2              | -           | -              |
| 2021 |                           | 2     | 1     | 4              | 1           | 2              |
| Total |                         | 35 (40.7) | 11 (12.8) | 26 (30.2) | 7 (8.1) | 7 (8.1) |

Figure 1: Antibiotic susceptibility pattern of isolated *B. pseudomallei* from clinical samples by Kirby Bauer disc diffusion method (n=86)

Discussion

Bangladesh was considered as ‘definite country’ for melioidosis in 2011 when organism was recovered for the first time from soil of Gazipur district. First case was reported at 1964 in a 29 year old British sailor who travelled through Chittagong, but melioidosis was diagnosed for the first time in a native Bangladeshi child in 1988. Since then it has been sporadically reported over last several decades from Bangladeshi immigrants and also from hospitalized patients of our country. There was no laboratory surveillance data to detect the isolation frequency and susceptibility pattern of *B. pseudomallei* in hospitals of Bangladesh. Therefore, we have reported the trends in isolation of *B. pseudomallei* from 68 cases by culture of different clinical samples during 2001 to 2021 in our Microbiology department.

In our study, most of the patients, 31(45.6%) belonged to the age group within range of 46-60 years, followed by 21 (30.9%) in the age group 31-45 years. Males were more commonly affected 83.8% (57/68). Previously Hantrakun et al., 2019 from Thailand had also reported the high frequency of melioidosis cases (54.4%) among the age groups of 45-64 years and a total of 67.9% infection had occurred in males.

One fourth (25%) of our patients were farmer, 13% housewife, 10% business man, 10% overseas worker returned from melioidosis endemic country (eg. Thailand, Malaysia, Singapore etc) and rest were construction workers, teacher, students and others (Table 2). Though some reports found no significant difference among different...
occupational groups, but few reported a definitive history of soil exposure and occupational activities in this group of patients. Interestingly one of our culture confirm case was diagnosed from the staff of our Microbiology lab in the year 2020 having DM. He is a 46-year-old laboratory worker who has been disinfecting and cleaning the culture tubes and plates for last 10 years. Initially, he was diagnosed clinically as rickettsial fever and treated with doxycycline for 10 days. Blood culture and triple antigen tests were found negative. Later on *B. pseudomallei* was isolated from culture of aspirated pus of subcutaneous abscess in front of anterior angle of right neck. Complete remission had occurred with definitive treatment of acute phase with injection ceftazidime for 14 days followed by oral co-trimoxazole for 3 months. This might be the first documented case of accidental occupational exposure to *B. pseudomallei* from Bangladesh. Very few cases of laboratory acquired melioidosis was reported previously.

Diabetes mellitus (DM) was identified as major underlying risk factor (RR 5.9-13.1) for *B. pseudomallei* infection especially in South East Asia like India, Thailand, Malaysia and Australia (30% to 82% cases). In our study 88.2% of melioidosis patient have DM. As melioidosis is commonly detected in patients having uncontrolled sugar level, most of the previously reported cases were detected from this tertiary care hospital which is the largest diabetes referral centre of Bangladesh.

Average annual isolation rate of *B. pseudomallei* was 5.6 (68/12 years) from different clinical samples in our center. Highest number of this offending bacteria was identified in 2015 (13 isolates) and 2019 (10 isolates). Majority of the organism were isolated from blood (40.7%) and pus/wound swab (30.2%) sample as septicemia (51.4%) and skin/soft tissue abscess (29.4%) were the most common presentations detected among these melioidosis cases. Major obstacles in identification of *B. pseudomallei* from unsterile sample like sputum, throat swab or rectal swab/ stool is overgrowth of normal flora which may be overlooked by the laboratory personnel. Isolation frequency from these unsterile sites is perhaps further increased by the use of a selective broth preenrichment or Ashdown agar media when clinically suspected.

Detection of *B. pseudomallei* from blood culture in severe disease is associated with higher mortality. In our laboratory, the blood culture was found positive 77.3% (17/22) of expired melioid patients. Some of the cases had died before the culture results were confirmed. So, for early diagnosis and prompt intervention against this deadly disease, high index of suspicion from both clinician and laboratory personnel is a prerequisite. A series of clinical trials have shown that the mortality from melioidosis can be significantly reduced (from 50% to 10%) by appropriate antibiotic treatment. All the isolates in our study were found sensitive (>95%) to ceftazidime, carbapenem, piperacillin-tazobactum, amoxicillin-clavulanic acid and tetracycline. Though, 46.6% of our strain were found resistant to co-trimoxazole by disc diffusion method, but some of these strains were further evaluated by MIC methods. 12 were found to be sensitive. Ciprofloxacin is not recommended antibiotic for treatment of melioidosis unless there are no alternatives.

Therefore, identification and antibiotic sensitivity pattern of this specific organism is very much important as treating this case with ordinary antibiotic regimen is ineffective and the bacterium is intrinsically resistant to many antibiotics.

**Conclusions**

Melioidosis is largely underrecognized by our health care policy makers due to underreporting of fatal cases. It should be included as notifiable diseases in national surveillance system of Bangladesh. We conducted retrospective data analysis from our laboratory records to determine the trends of isolation of the causative organism, *B. pseudomallei* from different clinical samples and their susceptibility pattern. Awareness, workshop and training for laboratory personnel and clinician of possible variation in presentation and diagnosis of melioidosis cases should be provided countrywide.

**Acknowledgments**

We are grateful to all the staff of department of Microbiology and department of Medicine, BIRDEM general hospital for their support in diagnosis and sample collection of melioidosis cases.

**Funding**

No funding is required for this study.

**Conflict of interest**

The authors have no conflict of interest to declare.

**Author contributions**

Lovely Barai: Writing-original draft, investigation, methodology, analysis of data (Lead)
caused by *Burkholderia pseudomallei* for melioidosis, a potentially fatal infectious disease. Bangladesh is documented as a ‘definite’ endemic country.

### Introduction

In 2015, a statistical model was constructed to estimate the burden of melioidosis. So far, approximately 54 cases have been confirmed in Bangladesh, with an estimated 1,65,000 and 16,931 cases likely misdiagnosed as it produces protean clinical manifestations and mimics tuberculosis or other pyogenic infections. Inexperienced laboratory staff frequently mistake these cases for contaminants. The antibody-based latex agglutination test (Melioidosis Rapid Latex Agglutination Test) is commonly used for the initial screening of patients. This test has a reported sensitivity of 85% and a specificity of 99.9%.

### Study Methods

**Mela Test**

A 0.5 McFarland suspension of each bacterial strain was used for testing. The sensitivity of the test was determined by comparing the results with the gold standard culture method.

**Isolation and Identification**

Blood culture and triple antigen tests were performed to confirm the diagnosis. The patients were diagnosed to be suffering from melioidosis if the test results were positive.

### Results

Out of 86 isolated *B. pseudomallei* cases (published and unpublished) and isolation trends of melioidosis cases in BIRDEM and department of Medicine, BIRDEM general hospital from 2001 to 2021, 51.5% were positive for Septicaemia. The highest number of cases involved construction workers and business men, with a male to female ratio of 3:1. 10% of the patients were construction workers, 10% were businessmen, 10% were carpenters, 10% were housewives, and 10% were overseas workers. 5.6% of the patients were below 15 years of age, while 14.7% were between 16-19 years. 29.4% of the patients were between 20-45 years of age. Males were more affected than females, with a male to female ratio of 2.5:1.

### Treatment

Melioidosis is treated with antibiotics for 10-14 days followed by eradication phase with oral parenteral drugs with ceftazidime (uncomplicated cases) or tetracycline, TMP-SMX (1.25/23.75 µg), gentamicin (10 (30 µg), meropenem/imipenem (10 µg), piperacillin-tazobactam (30 µg), ceftriaxone (250 µg) with amikacin (10 µg) for 10 days. Blood culture and triple antigen tests were performed to confirm the diagnosis. As melioidosis is often misdiagnosed, the use of antibiotics such as ceftazidime, minocycline, and cotrimoxazole is recommended for the initial treatment of suspected cases.

### Conclusion

Melioidosis is a serious infectious disease that affects a large number of patients in Bangladesh. The use of antibiotics such as ceftazidime and triple antibiotic therapy is recommended for the initial treatment of suspected cases. Further research is needed to improve diagnostic tools and treatment options.

### References

1. Jilani MS, Robayet JA, Mohiuddin M, Hasan MR, Ahsan CR, Haq JA. *Burkholderia pseudomallei*: its detection in soil and seroprevalence in Bangladesh. PLOS neglected tropical diseases. 2016 Jan 15;10(1):e0004301.

2. Limmathurotsakul D, Golding N, Dance DA, Messina JP, Pigott DM, Moyes CL, et al. Predicted global distribution of *Burkholderia pseudomallei* and burden of melioidosis. *Nature microbiology*. 2016 Jan 11;1(1):1-5.

3. Chowdhury FR, Jilani M, Alam S, Barai L, Rahman T, Saha MR, et al. Melioidosis in Bangladesh: a clinical and epidemiological analysis of culture-confirmed cases. *Tropical medicine and infectious disease*. 2018 Jun;3(2):40.

4. Saha SK, Samad T, Haque WM. Evidence of expanding geographic distribution of melioidosis in Bangladesh: reports of three cases. *BIRDEM medical journal*. 2021 Aug 22;11(3):239-42.

5. Dance DA. Melioidosis: the tip of the iceberg?. *Clinical microbiology reviews*. 1991 Jan;4(1):52-60.

6. Zueter A, Yean CY, Abumarzouq M, Rahman ZA, Deris ZZ, Harun A. The epidemiology and clinical spectrum of melioidosis in a teaching hospital in a North-Eastern state of Malaysia: a fifteen-year review. *BMC infectious diseases*. 2016 Dec;16(1):1-1.

7. Dance D. Treatment and prophylaxis of melioidosis. *International journal of antimicrobial agents*. 2014 Apr 1;43(4):310-8.

8. Lipuma JJ, Currie BJ, Lum GD, Vandomme PAR. *Burkholderia* Stenotrophomonas,Ralstonia,Cupriavidus, Pandorea, Brevundimonas, Comamonas, Delftia, and Acidovorax. In: *Murray PR, Baron EJ, Jorgensen JH, Landry ML, Pfaller MA*, editors. *Manual of clinical microbiology*. 9th ed. *Washington, DC: ASM Press*; 2007:749–69.

9. Bauer AW, Kirby WMM, Sherris JC, Tierch M. Antibiotic susceptibility testing by a standardized single disc method. *American journal of clinical pathology* 1966;45:493-6.

10. *Performance Standards for Antimicrobial Susceptibility Testing M100-S25*. Twenty-fifth Informational Supplement, vol. 35. 3rd ed. Wayne: Clinical and Laboratory Standards Institute; 2015.

11. *Clinical and Laboratory Standards Institute*. Methods for antimicrobial dilution and disk susceptibility testing of infrequently isolated or fastidious bacteria M45-A2, vol. 30. 2nd ed. Wayne: Clinical and Laboratory Standards Institute; 2010.

12. Dutta S, Haq S, Hasan MR, Haq JA. Antimicrobial susceptibility pattern of clinical isolates of *Burkholderia pseudomallei* in Bangladesh. *BMC research notes*. 2017 Dec;10(1):1-5.

13. Welcome trust. *Mahidol Oxford*. Oxford tropical medicine research programme. Standard operating procedure for isolation of *Burkholderia pseudomallei* from clinical samples. MORU SOP, MBL 3-8.0.M, version no. 1.5, November 2015.

14. Maegraith BG, Leithead CS. *Melioidosis*: A case-report. *Lancet* 1964;1:862-863.

15. Struelens MJ, Mondol G, Bennish M, Dance DA. Melioidosis in Bangladesh: a case report. *Transactions of the Royal Society of tropical medicine and hygiene*. 1988 Sep 1;82(5):777-8.

16. Uddin KN, Hessain M, Mansur A, Hoque MJA, Khan AR. Melioidosis-A Case Report. *Journal of Bangladesh college of physicians & surgeons* 2001;19:71-74.

17. Majumder MI, Haque MM, Ahmed MW, Alam MN, Rahman MW, Akter F, et al. Melioidosis in an adult male. *Mymensingh medical journal: MMJ*. 2013 Apr 1;22(2):413-6.

18. Barai L, Jilani MSA, Haq JA. Meliodosis-Case reports and review of cases recorded among Bangladeshi population from 1988-2014. *Ibrahim medical college journal* 2014;8(1):25-31.

19. Mahbub S, Al-Amin Z, Biswas SS, Jamal MS, Halder S. *Melioidosis-A rare infectious disease with atypical*
caused by century years ago, most of the physicians still missed and it is presumed that melioidosis is severely underreported of the offending organism. Laboratory diagnosis of staff frequently mistake it as contaminants. Typical co-trimoxazole or Amoxicillin/clavulanic acid for 12 for 10-14 days followed by eradication phase with oral or meropenem (in neuromelioidosis or complicated cases) which comprises two phases. In the first acute phase, 

In our study, most of the patients, 31(45.6%) belonged to microbe detected from clinical samples sent to

Burkholderia pseudomallei commonly affected age group was that between 46-60 weeks are recommended7. This study identifies melioidosis selective Ashdown agar media, Gram staining (bipolar

B. pseudomallei cases (published and unpublished) and isolation trends of detected from Mueller-Hinton agar (Mast diagnostics Ltd, UK) to Briefly, a 0.5 McFarland suspension of each bacterial used from B. pseudomallei

Major obstacles in identification of returned from melioidosis endemic country (eg. Thailand, housewife, 10% business man, 10% overseas worker et al28, 2019 from Thailand had also reported the high commonly affected 83.8% (57/68). Previously Hantrakun previously reported cases 4,16-27. There was no laboratory has been sporadically reported over last several decades occurred in males.

In presentation and diagnosis of melioidosis cases should determinant of Burkholderia pseudomallei and burden of soil exposure and occupational activities in this group

References

Colonization pattern of Gram positive organisms causing neonatal sepsis ... Hasnat et al

20. Rahim MA, Afroze SR, Barai L, Uddin KN. Melioidosis: Truly uncommon or Uncommonly diagnosed in Bangladesh? A case report. Birdem medical journal. 2015;5(1):49-51

21. Fatema K, Faruq MO, Ahsan AS, Ahmed F, Saha DK, Afroz F, et al. Disseminated melioidosis presenting as septic shock: An endemic disease of Bangladesh. International journal of current medical and applied sciences. 2015;5:200-2.

22. Fatema K, Ahsan AA, Barai L, Saha DK, Afroze SR, Faruq MO, et al. A case of fatal melioidosis presenting as septic arthritis and septicaemia. Bangladesh critical care journal. 2015 Sep 22;3(2):74-6.

23. Afroze SR , Rahim MA , Barai L, Uddin KN. Disseminated melioidosis involving skin and joint: a case report. Ibrahim medical college journal. 2015; 9(2):55-57.

24. Afroze SR, Rahman MR, Barai L, Hossain MD, Uddin KN. Successful treatment outcome of primary melioidosis pneumonia-a case report from Bangladesh. BMC research notes. 2016 Dec;9(1):1-5.

25. Saha DK, Ahsan ASMA, Faruq MOF, Fatema K, Ahmed F, Saha M. Hepatic Abscess as Presenting Feature of Meliodosis: A Case Report. BIRDEM medical journal 2016;6(1):43-45

26. Afroze SR, Haque HF, Afroz F, Barai L, Rahim MA, Haque MT, et al. Socio-demographic, clinical and laboratory characteristics of melioidosis: Four-year experience of managing consecutive 11 cases in a tertiary care hospital of Bangladesh. BIRDEM medical journal. 2017 Jan 24;7(1):28-37.

27. Rahim MA, Afroze SR, Afroz F, Haque HF, Barai L, Ahmed JU, et al. Melioidosis among returning workers in Bangladesh: imported or endemic. Sri Lankan journal of infectious diseases. 2017 Dec 20;7:34-5.

28. Hantrakun V, Kongyu S, Klayton P, Rongsunlee S, Day NP, Peacock SJ, et al. Clinical epidemiology of 7126 melioidosis patients in Thailand and the implications for a national notifiable diseases surveillance system. In Open forum infectious diseases 2019 Dec (Vol. 6, No. 12, p. ofz498). US: Oxford University Press.

29. Peacock SJ, Schweizer HP, Dance DA, Smith TL, Gee JE, Wuthiekanun V, et al. Management of accidental laboratory exposure to Burkholderia pseudomallei and B. mallei. Emerging infectious diseases. 2008 Jul;14(7):e2

30. Cheng AC, Currie BJ. Melioidosis: epidemiology, pathophysiology, and management. Clinical microbiology reviews. 2007 Jul;20(3):533-.

31. Koshy M, Jagannati M, Ralph R, Victor P, David T, Sathyendra S, et al. Clinical manifestations, antimicrobial drug susceptibility patterns, and outcomes in melioidosis cases, India. Emerging infectious diseases. 2019 Feb;25(2):316

32. Limmathurosakul D, Wongratanacheewin S, Teera-wattanasook N, Wongsuvan G, Chaisuksant S, Chetchotisakd P, et al. Increasing incidence of human melioidosis in Northeast Thailand. The American journal of tropical medicine and hygiene. 2010 Jun;82(6):1113.

33. Hassan MR, Pani SP, Peng NP, Voralu K, Vijayalakshmi N, Mehanderkar R, et al. Incidence, risk factors and clinical epidemiology of melioidosis: a complex socio-ecological emerging infectious disease in the Alor Setar region of Kedah, Malaysia. BMC infectious diseases. 2010 Dec;10(1):1-8.

34. Currie BJ, Fisher DA, Howard DM, Burrow JN, Lo D, Selva-Nayagam S, et al. Endemic melioidosis in tropical northern Australia: a 10-year prospective study and review of the literature. Clinical infectious diseases. 2000 Oct 1;31(4):981-6.

35. Samuel M, Ti TY. Interventions for treating melioidosis. Cochrane database of systematic reviews. 2002(4).

36. Dance D. Treatment and prophylaxis of melioidosis. International journal of antimicrobial agents. 2014 Apr 1;43(4):310-8.

37. Currie BJ. Melioidosis: evolving concepts in epidemiology, pathogenesis, and treatment. Seminars respiratory critical care medicine 2015;36:111e25.